title: Psoriasis triggered by infliximab in a patient with Behçet's disease.
abstract: OBJECTIVE
  To report a case of psoriasis triggered by anti-tumor necrosis factor-alpha (TNF-α) therapy in a uveitis patient with Behçet's disease.
  
  
  METHODS
  A 34-year-old man with established Behçet's disease was started on infliximab therapy for recurrent uveitis and showed an excellent response. After 2 years of infliximab treatment, he developed erythematous scaly plaques on both of his palms and heels. No clinical or serological evidence of infection was found, and there was no personal/family history of psoriasis. Histological examination of one lesion showed that it was consistent with psoriasis. Because of the development of hyperkeratotic skin lesions consistent with guttate psoriasis, the infliximab treatment was discontinued. Six months later, the psoriasis had resolved.
  
  
  CONCLUSIONS
  Blockade of TNF-α is an effective treatment for psoriasis as well as Behçet's disease. However, we have to consider new-onset psoriasis as an adverse side effect that can be triggered by anti-TNF-α therapy in Behçet's disease.
authors.affiliation: Department of Ophthalmology, Tokyo Medical and Dental University Graduate School of Medicine and Dental Sciences, Tokyo, Japan.
authors.forename: Yuko
authors.initials: Y
authors.lastname: Kawazoe
authors.forename: Sunao
authors.initials: S
authors.lastname: Sugita
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Yamada
authors.forename: Ai
authors.initials: A
authors.lastname: Akino
authors.forename: Keiko
authors.initials: K
authors.lastname: Miura
authors.forename: Manabu
authors.initials: M
authors.lastname: Mochizuki
mesh_terms: D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000009:adverse effects* / Q000627:therapeutic use; D001528:Behcet Syndrome / Q000188:drug therapy*; D005500:Follow-Up Studies; D006801:Humans; D000069285:Infliximab; D008297:Male; D011565:Psoriasis / Q000139:chemically induced* / Q000175:diagnosis; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab